A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Phase 3 Completed 1591 enrolled Satsuma Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

Timeline

Start: 2021-06-30
Primary completion: 2022-10-13
Completion: 2022-10-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dihydroergotamine	Small molecule	—	Intranasal

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Summary

Timeline

Drugs

Indications